Most Read Articles
2 days ago
Dairy consumption during adolescence or early adulthood does not appear to be associated with the overall risk of breast cancer, although results vary by hormone receptor status of tumours, a study has shown. Specifically, dairy intake is linked to higher ER–/PR– and lower ER+/PR+ cancer risk.
Roshini Claire Anthony, 5 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

3 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
4 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Tofacitinib use may increase risk of herpes zoster

20 Aug 2017

Treatment with tofacitinib appears to increase the risk of herpes zoster (HZ) compared with placebo, according to a recent study. The risk factors for heightened risk are Asian descent, increasing age, higher dose and prior biologic exposure.

Researchers calculated HZ incidence rates (IR; events per 100 patient-years) by using phases II and III and long-term extension data from the tofacitinib development programme in psoriasis. Cox-proportional hazard models were used to evaluate potential HZ risk factors.

Overall, HZ occurred in 130 (3.6 percent) patients on tofacitinib (IR, 2.55), no patients on placebo and two using etanercept (IR, 2.68). A total of nine patients (7 percent) were admitted to the hospital, and eight (6 percent) had multidermatomal HZ. There were no encephalitis, visceral involvement or deaths recorded. A total of 121 (93 percent) patients on tofacitinib continued or resumed use after HZ.

Asian race (hazard ratio [HR], 2.92), using tofacitinib 10 mg twice daily (vs 5 mg twice daily; HR, 1.72), prior use of biologics (HR, 1.72) and older age (HR, 1.30) were risk factors for HZ risk.

These findings support the results of two earlier studies, which concluded that HZ rates increased in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia and those using biologics. [Arthritis Rheumatol 2014;66:2675-84; Ann Rheum Dis 2016;75:1843-7]

In the current study, generalizability to other psoriasis populations might be limited. Furthermore, the effect of HZ vaccination was not examined.

“Tofacitinib is an oral Janus kinase inhibitor. Immunomodulatory therapies can increase the risk for HZ in patients with psoriasis,” according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Dairy consumption during adolescence or early adulthood does not appear to be associated with the overall risk of breast cancer, although results vary by hormone receptor status of tumours, a study has shown. Specifically, dairy intake is linked to higher ER–/PR– and lower ER+/PR+ cancer risk.
Roshini Claire Anthony, 5 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

3 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
4 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.